IPHA: Innate Pharma S.A. ADS Stocks News on November 20, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

IPHA

Business Wire

3 days ago

Innate Pharma to Present at Jefferies Global Healthcare Conference

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

IPHA

Business Wire

7 days ago

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

IPHA

MT Newswires

10 days ago

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

IPHA

Business Wire

10 days ago

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

IPHA

Zacks

14 days ago

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

IPHA

Business Wire

15 days ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

IPHA

Business Wire

a month ago

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

High Growth Tech Stocks In Europe For June 2025

IPHA

Simply Wall St.

5 months ago

High Growth Tech Stocks In Europe For June 2025

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

IPHA

Business Wire

5 months ago

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

IPHA

Business Wire

5 months ago

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

IPHA

Business Wire

6 months ago

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Outcome of Innate Pharma’s 2025 Annual General Meeting

IPHA

Business Wire

6 months ago

Outcome of Innate Pharma’s 2025 Annual General Meeting

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

IPHA

Business Wire

6 months ago

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

IPHA

Business Wire

6 months ago

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

IPHA

Business Wire

6 months ago

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

IPHA

Business Wire

6 months ago

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

IPHA

Business Wire

6 months ago

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

Innate Pharma announces conference call and webcast for Q1 2025 business update

IPHA

Business Wire

6 months ago

Innate Pharma announces conference call and webcast for Q1 2025 business update

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

IPHA

Business Wire

7 months ago

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

IPHA

Business Wire

7 months ago

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Innate Pharma And 2 Other European Penny Stocks To Watch

IPHA

Simply Wall St.

7 months ago

Innate Pharma And 2 Other European Penny Stocks To Watch

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

IPHA

Business Wire

7 months ago

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

IPHA

Benzinga

7 months ago

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

IPHA

MT Newswires

7 months ago

Innate Pharma, Sanofi Finalize Investment

Innate Pharma Announces €15M Investment by Sanofi

IPHA

Business Wire

7 months ago

Innate Pharma Announces €15M Investment by Sanofi

IPHA

MT Newswires

7 months ago

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

IPHA

Business Wire

7 months ago

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

IPHA

MT Newswires

7 months ago

Innate Pharma to Propose Corporate Governance Structure Change

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

IPHA

Business Wire

7 months ago

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

IPHA

Business Wire

7 months ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

IPHA

Business Wire

8 months ago

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

European Penny Stocks To Watch In March 2025

IPHA

Simply Wall St.

8 months ago

European Penny Stocks To Watch In March 2025

IPHA

GuruFocus.com

8 months ago

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

IPHA

Business Wire

8 months ago

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

IPHA

Business Wire

8 months ago

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

IPHA

Business Wire

8 months ago

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

IPHA

Business Wire

8 months ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

IPHA

Business Wire

9 months ago

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

IPHA

MT Newswires

9 months ago

Top Premarket Gainers

Innate’s lacutamab gains FDA breakthrough therapy designation

IPHA

Pharmaceutical Technology

9 months ago

Innate’s lacutamab gains FDA breakthrough therapy designation

$Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome$

IPHA

Business Wire

9 months ago

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

3 Promising Penny Stocks With Market Caps Under US$500M

IPHA

Simply Wall St.

10 months ago

3 Promising Penny Stocks With Market Caps Under US$500M

IPHA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Mixed Premarket Monday

Innate Pharma doses first patient in Nectin-4 ADC trial

IPHA

Clinical Trials Arena

10 months ago

Innate Pharma doses first patient in Nectin-4 ADC trial

IPHA

MT Newswires

10 months ago

Innate Pharma Doses First Patient in Phase 1 Trial of Cancer Drug Candidate

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

IPHA

Business Wire

10 months ago

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

IPHA

Business Wire

10 months ago

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

IPHA

Business Wire

10 months ago

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

IPHA

MT Newswires

10 months ago

Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth

Innate Pharma Announces Transformative Strategy to Accelerate Growth

IPHA

Business Wire

10 months ago

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

IPHA

Business Wire

a year ago

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

3 Promising Penny Stocks With Market Caps Under US$300M

IPHA

Simply Wall St.

a year ago

3 Promising Penny Stocks With Market Caps Under US$300M

Innate Pharma SA Reveals Promising Lacutamab Trial Results

IPHA

TipRanks

a year ago

Innate Pharma SA Reveals Promising Lacutamab Trial Results

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

IPHA

Business Wire

a year ago

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

IPHA

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Premarket Friday

IPHA

MT Newswires

a year ago

Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

IPHA

Business Wire

a year ago

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

IPHA

Business Wire

a year ago

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma Releases Its 2025 Financial Calendar

IPHA

Business Wire

a year ago

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

IPHA

Business Wire

a year ago

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Discover 3 Promising Penny Stocks With Over US$90M Market Cap

IPHA

Simply Wall St.

a year ago

Discover 3 Promising Penny Stocks With Over US$90M Market Cap

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

IPHA

Business Wire

a year ago

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

IPHA

Business Wire

a year ago

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

IPHA

Business Wire

a year ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

IPHA

Business Wire

a year ago

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

IPHA

MT Newswires

a year ago

Innate Pharma Names Jonathan Dickinson as New CEO, Chairman

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

IPHA

Business Wire

a year ago

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

IPHA

Business Wire

a year ago

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

IPHA

MT Newswires

a year ago

Innate Pharma Receives FDA Clearance for Phase 1 Trial of Cancer Treatment; Shares Rise

FDA grants IND clearance for Innate Pharma’s solid tumour trial

IPHA

Clinical Trials Arena

a year ago

FDA grants IND clearance for Innate Pharma’s solid tumour trial

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

IPHA

Business Wire

a year ago

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Innate Pharma Reports First Half 2024 Business Update and Financial Results

IPHA

Business Wire

a year ago

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

IPHA

Business Wire

a year ago

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

IPHA

Business Wire

a year ago

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

IPHA

Business Wire

a year ago

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Innate Pharma Announces Its Participation in Upcoming Investor Conference

IPHA

Business Wire

a year ago

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024

IPHA

Business Wire

a year ago

Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024

Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024

IPHA

Business Wire

a year ago

Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024

IPHA

MT Newswires

a year ago

Innate Pharma Reports 'Promising and Durable' Results From Phase 1/2 Monotherapy Targeting Blood Cancers

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

IPHA

Business Wire

a year ago

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

IPHA

Business Wire

a year ago

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

IPHA

Business Wire

a year ago

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

IPHA

Business Wire

a year ago

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Outcome of Innate Pharma’s 2024 Annual General Meeting

IPHA

Business Wire

a year ago

Outcome of Innate Pharma’s 2024 Annual General Meeting

Innate Pharma: Clarification Regarding SAR443579 Designation

IPHA

Business Wire

a year ago

Innate Pharma: Clarification Regarding SAR443579 Designation

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

IPHA

Business Wire

2 years ago

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

IPHA

Business Wire

2 years ago

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

IPHA

Business Wire

2 years ago

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

IPHA

Business Wire

2 years ago

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

IPHA

Business Wire

2 years ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

IPHA

Zacks

2 years ago

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

IPHA

Business Wire

2 years ago

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

IPHA

Business Wire

2 years ago

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

IPHA

Business Wire

2 years ago

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

IPHA

Insider Monkey

2 years ago

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

IPHA

Business Wire

2 years ago

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

Innate Pharma Announces Its Participation to Upcoming Investor Conference

IPHA

Business Wire

2 years ago

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

IPHA

Business Wire

2 years ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

$Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma$

IPHA

Business Wire

2 years ago

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

IPHA

Business Wire

2 years ago

Latest Innate Pharma S.A. ADS (IPHA) News on November 20, 2025

Share on Social Networks: